JSLLJSLL Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market CapN/A
Primary DriverGrowth Sustainability
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
14 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in growth sustainability. This indicates that forensic pressure is currently receding. Risk levels are improving.

35.4th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹590.6▲19.99%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Growth Sustainability
+10.0 pts
Stability Adjustment
+4.0 pts
Final Composite Risk14 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 14 over 12 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
What to Watch Next Quarter
  • Working capital efficiency
  • Inventory turnover

Active Risk Objects (2)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ2 FY2026
Working capital expansion detected: Receivable days increased by 26.9%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Inventory Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (75.1%) significantly outpaced revenue growth (-14.3%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)47.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+52.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹590.6(+19.99%)
1M Divergence-14.76%
1 Week-6.97%
1 Month-12.49%
6 Months-15.53%
1 Year-71.46%
2 Year-45.53%
3 Year+150.07%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in growth sustainability remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

JSLL • MARKET STRUCTURE

Stage 4 — Declining

The company is in a defensive phase. Sentiment and fundamentals are deteriorating under persistent downward pressure, indicating elevated risk levels.

Stage Transition Prob.0%
Trend QualityDeteriorating
Phase Progression
Phase Progression Score0%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing0%
CoinTree Momentum
Composite Z-Score-0.6678σ
Weakening momentum trend
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#2282 of 2716
Top 84.02% in momentum strength
Timeframe Sparklines
1W-7.0%
1M-12.5%
6M-15.5%
Weinstein Indicators
150 DMA₹680.55
200 DMA₹696.39
150 DMA Slope-2.1146%Declining
Relative Strength-10.04%Lagging
Relative Turnover (RTR)1.4250
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).
JSLLJSLL
14 Risk
Sector %ile35th
Delta-5
Active Flags2
Accel+0
Growth Sustainability

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

AARTIPHARMAarti Pharmalabs Limited
35 Risk
Sector %ile81th
Delta0
Active Flags18
Accel+0
Earnings Quality

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Inventory Stress

2026

Working Capital Expansion

2025

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20268102222540
FY2025475916911
FY202214811167